Keywords: Insmed, Arikace, NTM lung disease, USA, FDA, Clinical hold lifted

FDA lifts hold on Insmed Arikace trial

Article | 23 January 2012

Print This

USA-based biopharma company Insmed’s (Nasdaq CM: INSM) shares leapt 33.7% to $5.08 on Friday, after the company revealed that the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in